|
A Randomized Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum Resistant or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer (GY005) |
III |
|
|
A Randomized Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer with HER2 Amplification (S1613) |
II |
|
|
A Randomized Trial Comparing Adjuvant Pembrolizumab vs Standard of Care Observation in Completely Resected Merkel Cell Carcinoma of Skin (EA6174) |
III |
|
|
A Randomized Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma (EA6134) |
III |
|
|
A Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel vs Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers (S1815) |
III |
|
|
A Randomized Trial of Paclitaxel and Carboplatin vs Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemo-naive Sex Cord Stromal Tumors of the Ovary (GOG0264) |
II |
|
|
A Randomized Trial of Pelvic Radiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic Only Recurrence of Carcinoma of the Uterine Corpus (GOG-0238) |
|
|
|
A Randomized Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment (CT4006) |
III |
|
|
A Randomized, Double Blind Phase III Study of Pembrolizumab vs Placebo in Combination with NeoAdjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High Risk Early Stage Hormone Positive, HER2 Negative Breast Cancer (MK3475-756) |
III |
|
|
A Randomized, Double Blind Placebo Controlled Pilot Study of an Oral Selective Peripheral Opioid Receptor Antagonist in Advanced NonSmall Cell Lung Cancer (A221504) |
|
|
|
A Randomized, Double Blind Placebo Controlled Study Evaluating teh Efficacy and Safety of Copanlisib in Combination with Rituximab In Relapsed Indolent B-Cell NonHodgkins Lymphoma (CHRONOS-3) |
III |
|
|
A Randomized, Double Blind Study of Cabozantinib vs Placebo in Patients with Advanced Neuroendocrine or Carcinoid Tumors after Progression on Everolimus (A021602) |
III |
|
|
A Randomized, Double Blind Trial of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-016) |
III |
|
|
A Randomized, Double-Blind Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First Line HER-2 Positive Metastatic Breast Cancer (BR004) |
III |
|
|
A Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-Line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer (INTR@PID) |
II |
|
|
A Randomized, Placebo-Controlled, Double Blind Study of Adjuvant Cemiplimab vs Placebo After Surgery and Radiation Therapy In Patients with High Risk Cutaneous Squamous Cell Carcinoma (R2810-ONC-1788) |
|
|
|
A Sequential 2 Arm Open Label Study to Evaluate teh Effects of Encorafenib in Combination with Binimetinib In Patients with BRAF V600 Mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors (Array-818-103) |
I |
|
|
A Study Comparing Venetoclax + Fulvestrant vs Fulvestrant In Women with Estrogen Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy |
II |
|
|
A study evaluating the safety and efficacy of Polatuzumab vedotin in combination with Rituximab plus Gemcitabine plus Oxaliplatin (R-GEMOX) versus R-GEMOX alone in relapsed/refractory Diffuse Large B Cell Lymphoma (MO40598) |
III |
|
|
A study of Abemaciclib, and CDK 4/6 inhibitor, in combination with Fulvestrant compared to chemotherapy in women with HR positive, HER2 negative advanced breast cancer with visceral metastases (I3Y-MC-JPCU) |
|
|
|
A Study of ASP1948, Targeting Immune Modulatory Receptor in Subjects with Advanced Solid Tumors (1948-CL-0101 |
I |
|
|
A Study of Cabozantinib Compared with Placebo in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR targeted Therapy (XL184-311) |
|
|
|
A Study of Daratumumab/rHuPH20 Plus Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant MaintenanceTherapy in Patients with Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (S1803) |
III |
|
|
A Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum Based Regimen or Anti-PD-1/PD-L-1 Based Immunotherapy (18283) |
II |
|
|
A Study of IMO-2125 in Combination with Ipilimumab vs Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) |
|
|
